PF-Atlas › Mechanisms › China Registry

China Registry in IPF

Mechanism of action · idiopathic pulmonary fibrosis

Overview

China Registry is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 2 drugs and 2 clinical trials acting through this mechanism.

Drugs targeting China Registry

VUM02 InjectionV001-BCMA

Clinical trials

VUM02 Injection — NCT06230822V001-BCMA — NCT07339540
Medical disclaimer. This is a research summary, not medical advice.